Interpreting the Association Between Cytokines and Autoimmune Diseases--Topic 3

Cytokines: Key Drivers of Autoimmune Pathogenesis and Potential Therapeutic Targets

Cytokines are important protein mediators of immunity, inflammation, cell behavior. Given that these are the main biological processes involved in autoimmunity, there is evidence that cytokines play an important role in the pathogenesis of autoimmune diseases.

In Topic 1 and Topic 2, we have examined the connection between cytokines and 6 major autoimmune diseases. These diseases are closely linked to cytokine imbalance. However, with over 100 refractory AIDs discovered, overcoming them remains difficult. This issue, we will explore the connections between cytokines and three other autoimmune diseases.

The Role of Cytokines in AS, PsA and SSc

The pathogenesis of ankylosing spondylitis (AS) is closely related to dysregulation of immune function, where the abnormal release of inflammatory factors and imbalance of immune cells play crucial roles in the disease process.

Excessive levels of cytokines such as TNF-α, IL-17, and IL-23 can promote inflammatory responses and accelerate joint damage. Monoclonal antibody drugs targeting these key cytokines, such as adalimumab, etanercept, secukinumab, and guselkumab, have become important cytokine-targeted therapies for the treatment of AS. Furthermore, IL-6 inhibitors have also demonstrated promising clinical efficacy in recent years, offering the potential to fundamentally curb disease progression.

In summary, precisely modulating key inflammatory factors may provide an effective means to control the development of AS and improve patient prognosis.

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can lead to joint destruction and deformities, significantly impacting the patient's quality of life. With a deeper understanding of the pathological mechanisms of PsA, new treatment options have emerged, which have opened up new directions for the management of PsA.

• TNF-α Inhibitors

TNF-α is the most potent proinflammatory cytokine known to date and plays a critical role in PsA. TNF-α inhibitors can significantly alleviate symptoms in patients. Currently, there are five TNF-α inhibitors approved by the FDA for the treatment of PsA: infliximab, etanercept, adalimumab, golimumab and golimumab.

These TNF-α inhibitors have demonstrated efficacy in managing the symptoms and progression of PsA.

• IL-17 Inhibitors

IL-17A is a member of the IL-17 cytokine family and plays a critical role in the skin lesions, arthritis, and enthesitis associated with PsA. Several IL-17 inhibitors are currently in development, and two have been approved by the FDA for the treatment of PsA: secukinumab and ixekizumab.

These IL-17 inhibitors have demonstrated efficacy in managing the various manifestations of PsA by targeting this key inflammatory cytokine.

• IL-12/IL-23 Inhibitors

The IL-12/IL-23 axis is an important pathological pathway in the development of psoriatic arthritis (PsA). Targeting the IL-23p19 subunit, the related inhibitor tildrakizumab is currently in phase III clinical trials. The IL-12/IL-23 inhibitors that have been approved by the FDA for the treatment of PsA include: ustekinumab, guselkumab and risankizumab.

These therapies that block the IL-12/IL-23 signaling have shown efficacy in managing the diverse manifestations of PsA by intervening in this key inflammatory pathway.

Systemic Sclerosis (SSc) is a rare systemic autoimmune disease characterized by a high degree of clinical heterogeneity. Immune cells release a variety of cytokines and growth factors, which are believed to play key roles in the inflammatory and fibrotic processes of SSc.

Cytokines such as IL-1, IL-4, IL-13, IL-17, IL-23, and IL-31 are involved in regulating the inflammatory, vascular, and fibrotic processes in SSc, making them potential therapeutic targets. Elevated IL-6 levels are closely associated with poor prognosis, also making it a potential target for SSc treatment.

Therapies targeting the TGF-β pathway, such as fresolimumab, have entered phase I clinical trials, brodalumab, an IL-17 inhibitor that can induce vascular disease, inflammation, and fibrosis, has also entered phase III clinical trials.

Additionally, inhibiting IL-1, IL-31, and interferon signaling pathways have shown promising prospects for the treatment of SSc.

ACROBiosystems Advances Autoimmune Disease Treatment with Novel Therapeutic Solutions

ACROBiosystems is providing you with a series of recombinant cytokines and their receptors, including Interleukins, Growth Factors, TNFs, Chemokines, CSFs, IFNs, and Complement Components with high purity, high bioactivity, and high batch-to-batch consistency to accelerate your autoimmune diseases drug development programs.

Reliable ELISA Kits for Precise Autoimmune Analysis

We have launched ready-to-use ELISA kits with rigorously quality control, ensuring the precision, stability, and consistency of the analysis results, to better meet your experimental needs.

Related Articles